Condition: Cancer · Sponsor: Peking University Cancer Hospital & Institute
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the clinical predictive value of 68Ga-DOTA-BPP in subjects with triple-negative breast cancer. The visual and semiquantitative methods will be used to assess the PET/CT images
This description comes directly from the study's public registry record.
Qian Zhang · 13765839835 · 1806708691@qq.com
Hua Zhu, M.D · 13671224863 · zhuhuabch@pku.edu
Always discuss trial participation with your own doctor first.
| Ethics Committee of Peking University Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06203119